Cel-Sci Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
25.3%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$3.07next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Fiscal Year 2026 Annual Financial Results (Form 10-K) | 29 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Confirmatory Registration Study Enrollment Progress Quarterly0.0%Target: 212 patients
Cash and Cash Equivalents Quarterly1.9M
Saudi Arabia Regulatory Milestone (Breakthrough Medicine Designation) MonthlyTarget: Breakthrough Medicine Designation Approval
Watch Items
- Going Concern Risk and Cash RunwayTrigger: Cash balance falling below $1.0 million without an active capital raise or partnership upfront payment.Action: Evaluate immediate dilutive equity offerings, best-efforts placements, or strategic licensing agreements to sustain operations.
- U.S. Confirmatory Registration Study InitiationTrigger: Failure to enroll the first patient by Fall 2026.Action: Assess clinical site readiness, investigator engagement, and potential protocol adjustments to accelerate patient recruitment.
- Saudi Arabia Partnership ExecutionTrigger: Delay or rejection of the Breakthrough Medicine Designation by the Saudi Food and Drug Authority (SFDA).Action: Re-engage with Saudi partner Amarox to address SFDA scientific queries and revise the local regulatory strategy.
Research as of 19 Jun 2026